Comparative Pharmacology
Head-to-head clinical analysis: LABID versus VIZZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABID versus VIZZ.
LABID vs VIZZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LABID is a fixed-dose combination of metformin (biguanide) and glipizide (sulfonylurea). Metformin primarily decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity via AMPK activation. Glipizide stimulates insulin secretion from pancreatic beta-cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
400 mg orally twice daily.
80 mg orally once daily
None Documented
None Documented
8–12 hours in healthy adults; prolonged to 24–48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 18-24 hours. Steady-state is reached within 4-5 days; accumulation may occur in renal impairment.
Renal: 70–80% unchanged; fecal: 15–20% (biliary); metabolism accounts for <10%.
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 60% of a dose is excreted in urine as metabolites, 30% in feces, and <5% unchanged.
Category C
Category C
Unknown
Unknown